Skip to main content

Table 2 Adjusted HRs of breast cancer-specific mortality associated with race (black women vs. white women)

From: Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

 

White

Black

Model 1a

Model 2a,b

 

Person-years

Death (No.)

Person-years

Death (No.)

HR

95% CI

HR

95% CI

All women

6246

131

4471

141

1.54

1.21 to 1.97

1.26

0.99 to 1.62

Subtypes defined by ER/PR/HER2

       

 TN

1341

46

1381

57

1.21

0.81 to 1.83

1.08

0.71 to 1.64

 Luminal A

3853

56

2235

47

1.52

1.01 to 2.28

1.23

0.81 to 1.86

 Luminal B

643

16

481

14

1.67

0.67 to 4.19

0.98

0.27 to 3.58

 HER2-enriched

408

13

375

23

2.27

0.87 to 5.93

1.95

0.71 to 5.37

Subtypes defined by ER/PR/HER2/p53

       

 TN/p53-

825

24

664

30

1.38

0.76 to 2.51

1.32

0.70 to 2.47

 TN/p53+

516

22

717

27

1.04

0.56 to 1.93

1.03

0.55 to 1.95

 Luminal A/p53-

3262

39

1814

33

1.50

0.92 to 2.44

1.22

0.74 to 2.04

 Luminal A/p53+

591

17

421

14

1.10

0.40 to 2.97

0.81

0.28 to 2.39

Younger women (ages 35–49 yrs)

3066

83

2248

84

1.45

1.06 to 1.99

1.21

0.87 to 1.66

Subtypes defined by ER/PR/HER2

       

 TN

861

33

785

39

1.30

0.80 to 2.12

1.11

0.67 to 1.84

 Luminal A

1623

31

1069

22

1.16

0.65 to 2.05

1.01

0.56 to 1.80

Subtypes defined by ER/PR/HER2/p53

       

 TN/p53-

513

17

372

19

1.38

0.67 to 2.85

1.39

0.66 to 2.95

 TN/p53+

349

16

413

20

1.14

0.56 to 2.35

1.07

0.51 to 2.25

 Luminal A/p53-

1329

23

792

12

0.86

0.41 to 1.80

0.77

0.36 to 1.63

 Luminal A/p53+

294

8

277

10

1.04

0.23 to 4.63

0.80

0.17 to 3.72

Older women (ages 50–64 yrs)

3181

48

2223

57

1.71

1.16 to 2.53

1.38

0.93 to 2.04

Subtypes defined by ER/PR/HER2

       

 TN

480

13

596

18

1.00

0.47 to 2.10

1.03

0.48 to 2.20

 Luminal A

2231

25

1167

25

2.07

1.16 to 3.70

1.51

0.83 to 2.74

Subtypes defined by ER/PR/HER2/p53

       

 TN/p53-

313

7

292

11

1.56

0.52 to 4.67

1.34

0.41 to 4.37

 TN/p53+

167

6

304

7

0.79

0.23 to 2.71

0.87

0.24 to 3.14

 Luminal A/p53-

1934

16

1022

21

2.53

1.27 to 5.04

1.89

0.93 to 3.86

 Luminal A/p53+

297

9

144

4

1.16

0.31 to 4.35

0.90

0.15 to 5.48

  1. HRs are from multivariable Cox proportional hazards regression models using age (in days) at diagnosis and at death or end of follow-up as the time scale and stratified by single years of age at diagnosis. aAdjusted for study site. bAdditionally adjusted for tumor stage. Abbreviations: HR, hazard ratio; CI, confidence interval. ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us